Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials.
adenocarcinoma
adjuvant chemotherapy
esophageal cancer
gastric cancer
histopathological regression
perioperative chemotherapy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Aug 2020
16 Aug 2020
Historique:
received:
30
06
2020
revised:
12
08
2020
accepted:
14
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). Survival and the pattern of recurrence of EGAC after FLOT and curative tumor resection are analyzed in a collective of patients treated outside clinical trials. Two-hundred-seventy-seven patients with EGAC (cT3-4 and/or cN+) were treated with perioperative FLOT-chemotherapy plus curative surgery between 2009 and 2018. Data were analyzed retrospectively from a prospective database. Two-hundred-twenty-eight patients were included in the analysis. Postoperative in-hospital mortality was 2%. The median survival was 61-months, and median recurrence-free survival was 42 months. Multivariate analysis identified postoperative nodal status and T-stage as independent predictors of improved overall and recurrence-free survival. Administration of adjuvant chemotherapy failed to be significant for overall survival but was an independent predictor of recurrence-free survival. Recurrence occurred after a median of 9 months (range 1-46 months). Eighty-nine percent of recurrence occurred during the first 24 months. The rate of local recurrence was low. After surgery for gastric cancer, the major recurrence site was peritoneal carcinomatosis (56%), while esophageal cancer recurred mostly as metastasis to distant organs (78%). The specific site of recurrence had no impact on overall survival time. Real-life application of FLOT shows oncologic results comparable to clinical trials. Recurrence after FLOT and surgery for EGAC occurs predominantly early within the first two years after surgery and in the form of distant organ metastasis for esophageal tumors or peritoneal carcinomatosis for gastric tumors.
Sections du résumé
BACKGROUND
BACKGROUND
The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). Survival and the pattern of recurrence of EGAC after FLOT and curative tumor resection are analyzed in a collective of patients treated outside clinical trials.
METHODS
METHODS
Two-hundred-seventy-seven patients with EGAC (cT3-4 and/or cN+) were treated with perioperative FLOT-chemotherapy plus curative surgery between 2009 and 2018. Data were analyzed retrospectively from a prospective database.
RESULTS
RESULTS
Two-hundred-twenty-eight patients were included in the analysis. Postoperative in-hospital mortality was 2%. The median survival was 61-months, and median recurrence-free survival was 42 months. Multivariate analysis identified postoperative nodal status and T-stage as independent predictors of improved overall and recurrence-free survival. Administration of adjuvant chemotherapy failed to be significant for overall survival but was an independent predictor of recurrence-free survival. Recurrence occurred after a median of 9 months (range 1-46 months). Eighty-nine percent of recurrence occurred during the first 24 months. The rate of local recurrence was low. After surgery for gastric cancer, the major recurrence site was peritoneal carcinomatosis (56%), while esophageal cancer recurred mostly as metastasis to distant organs (78%). The specific site of recurrence had no impact on overall survival time.
CONCLUSION
CONCLUSIONS
Real-life application of FLOT shows oncologic results comparable to clinical trials. Recurrence after FLOT and surgery for EGAC occurs predominantly early within the first two years after surgery and in the form of distant organ metastasis for esophageal tumors or peritoneal carcinomatosis for gastric tumors.
Identifiants
pubmed: 32824326
pii: jcm9082654
doi: 10.3390/jcm9082654
pmc: PMC7464040
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Cancer. 2016 Jul 19;16:503
pubmed: 27435280
Surg Oncol. 2020 Jun;33:177-188
pubmed: 28684226
J Surg Oncol. 2019 Dec;120(7):1148-1153
pubmed: 31544969
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Surg Oncol. 2014 Mar;109(3):287-93
pubmed: 24277235
J Clin Med. 2019 Oct 15;8(10):
pubmed: 31618869
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
Eur J Surg Oncol. 2015 Oct;41(10):1300-7
pubmed: 26253194
Ann Surg. 2003 Sep;238(3):339-47; discussion 347-8
pubmed: 14501500
Acta Oncol. 2012 Sep;51(7):906-14
pubmed: 22524212
Cancers (Basel). 2019 Oct 26;11(11):
pubmed: 31717799
J Gastrointest Surg. 2013 Jul;17(7):1193-201
pubmed: 23636882
Gastric Cancer. 2015 Jan;18(1):1-10
pubmed: 24638977
Ann Surg Oncol. 2015 Jan;22(1):324-30
pubmed: 25023544
Cancer Invest. 2014 Jul;32(6):272-84
pubmed: 24800782
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Cochrane Database Syst Rev. 2013 May 31;(5):CD008107
pubmed: 23728671
Cancer. 2017 Aug 1;123(15):2909-2917
pubmed: 28386965
Ann Oncol. 2012 Nov;23(11):2827-2834
pubmed: 22734012